top
Search terms
Results 1 - 8 of 8 - ordered by :
Escardio

“hs-cTn is the most important advance in cardiac biomarkers in the last decade due to the conduct of very large diagnostic studies and to extensive clinical development. Because of this, very ...

Date : 01/09/2019
Escardio

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart ...

Date : 27/08/2018
Escardio

Long-term antiplatelet monotherapy after stenting is safe but does not reduce the risk of death or heart attack compared to standard dual antiplatelet therapy, according to late breaking results from ...

Date : 27/08/2018
Escardio

Chronic coronary syndromes (CCS), of which angina pectoris is an important symptom, have a major societal impact, affecting our patients’ quality of life (QoL) with reduced physical endurance, ...

Date : 22/05/2018
Escardio

[...]the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) also found a consistently greater risk of haemorrhage in the 24-month dual therapy ...

Date : 30/08/2011
Escardio

The American College of Cardiology (ACC) and American Heart Association (AHA) have updated their 2007 joint guidelines for the management of patients with unstable angina and non-ST-elevation ...

Date : 01/04/2011
Escardio

Conversely, lifestyle, diabetes, dyslipidemia, cigarette smoking and hypertension contribute to most of the population-attributable risk in the large, international INTERHEART study of acute ...

Date : 01/09/2008
Escardio

The dark side of this debate was an unjustified alarm when results were presented in the general press which created unnecessary anxiety among the thousands of patients who have already received ...

Date : 31/08/2008